Q3 2026 Management View Donald Nolan, CEO & Executive Chairman of the Board, began the call by announcing a leadership ...

Kiniksa Pharmaceuticals announces Phase 2/3 trial for KPL-387, targeting recurrent pericarditis, expected mid-2025. Data available in late 2026. Kiniksa Pharmaceuticals announced that it is set to ...

Annovis reported topline data from a Phase 2/3 trial in Alzheimer's disease, but the trial was a failure. The exclusion of 37% of the patient population and the focus on mild AD patients were not ...

Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025. The company has noted that data from the ongoing Phase 1 ...

The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH), the company is racing to phase 3 as ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...

Mutuum Finance (MUTM), a decentralized finance project developing a non-custodial lending and borrowing protocol, has ...

Nagpur Metro’s Phase 3 expansion is poised to be significantly broader than originally planned, with authorities now ...

Migration, as visible in other government data as well, has been the primary reason for the large-scale deletion of electors' names in many states.